- 作者：You-Jin Jang M.D. ; Ph.D. ; Jong-Han Kim M.D. ; Ph.D. ; Sung-Soo Park M.D. ; Ph.D. ; Seong-Heum Park M.D. ; Ph.D. ; Seung-Joo Kim M.D. ; Ph.D. ; Chong-Suk Kim M.D. ; Ph.D. ; Young-Jae Mok M.D. ; Ph.D. ; ; ; yjmok@korea.ac.kr
- 关键词：chemosensitivity test ; tumor heterogeneity ; gastric cancer
- 刊名：Journal of Surgical Research
- 出版年：2011
- 出版时间：December 2011
- 年：2011
- 卷：171
- 期：2
- 页码：657-662
- 全文大小：262 K
Background
The objective of this study was to compare the chemosensitivity of primary tumor and metastasized lymph node from patient with gastric adenocarcinoma.Materials and Methods
We studied 26 gastric cancer patients with lymph node metastasis who underwent gastric resection at the Korea University Guro Hospital from Feb 2007 to July 2008. The chemosensitivity of primary tumor and metastatic lymph node were studied using an adenosine triphosphate-based chemotherapy response assay (ATP-CRA).
Results
The concordance rate of the ATP-CRA test was 30.8 % (8/26). The concordance rate between primary tumor and metastatic N2 group lymph node was only 9.1 % (1/11). The metastatic tumor inhibition rates with 5-fluorouracil, cisplatin, doxorubicin, and oxaliplatin were higher than the inhibition rates for primary tumor. Tumor inhibition rates was significantly different between primary tumor and metastatic tumor after doxorubicin treatment (27.734 ¡À 20.95 versus 38.403 ¡À 26.87, P = 0.021). We detected simple correlations of tumor inhibition rates between?primary and metastatic tumors with cisplatin (r?=?0.661, P < 0.001) and doxorubicin (r = 0.475, P?= 0.031).
Conclusions
We observed differences between first choice chemotherapeutic agents based on ATPCRA tests of primary tumor and metastatic tumor in lymph node. Therefore, chemotherapeutic agents should be carefully selected for adjuvant chemotherapy using a chemosensitivity test.